Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
November 14, 2024 16:10 ET
|
Fortress Biotech, Inc.
Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally...
Fortress Biotech to Participate in October 2024 Investor Conferences
September 26, 2024 08:30 ET
|
Fortress Biotech, Inc.
MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term...
Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements
September 20, 2024 08:30 ET
|
Fortress Biotech, Inc.
MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to...
Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024 08:30 ET
|
Fortress Biotech, Inc.
MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term...
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
August 13, 2024 16:05 ET
|
Fortress Biotech, Inc.
PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab to...
Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027
July 25, 2024 08:30 ET
|
Fortress Biotech, Inc.
MIAMI, July 25, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”, or the “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to...
Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
July 05, 2024 16:05 ET
|
Fortress Biotech, Inc.
MIAMI, July 05, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO; FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance...
Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
May 16, 2024 08:00 ET
|
Fortress Biotech, Inc.
MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term...
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 15, 2024 16:15 ET
|
Fortress Biotech, Inc.
Fortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025 FDA...
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation
May 14, 2024 08:30 ET
|
Fortress Biotech, Inc.
Helocyte, a majority-owned subsidiary of Fortress Biotech, is developing Triplex for the prevention and treatment of cytomegalovirus in multiple transplant indications, as well as HIV Clinical trial...